Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs

Cancer Research

Volumn 62, Issue 23, 2002, Pages 6938-6943

  Bocci, Guido ^a   Nicolaou, K C ^b,c   Kerbel, Robert S ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; BMS 275183; DOXORUBICIN; EPOTHILONE B; PACLITAXEL; TAXANE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG SENSITIVITY; ENDOTHELIUM CELL; FIBROBLAST; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LONG TERM CARE; LOW DRUG DOSE; MICROVASCULATURE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CELL DIVISION; CELL SURVIVAL; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; EPOTHILONES; HUMANS; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0036897097     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Miller, K. D., Sweeney, C. J., and Sledge, G. W. Redefining the target: Chemotherapeutics as antiangiogenics. J. Clin. Oncol., 19: 1195-1206, 2001.
2. Polverini, P. J., and Novak, R. F. Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantrene. Biochem. Biophys. Res. Commun., 140: 901-907, 1986.
3. Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., and Augustin, H. G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res., 60: 1388-1393, 2000.
4. Browder, T., Butterfield, C. E., Kraling, B. M., Marshall, B., O'Reilly, M. S., and Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res., 60: 1878-1886, 2000.
5. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D., Bohlen, P., and Kerbel, R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest., 105: R15-R24, 2000.
6. Hanahan, D., Bergers, G., and Bergsland, E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest., 105: 1045-1047, 2000.
7. Klement, G., Mayer, B., Huang, P., Man, S., Bohlen, P., Hicklin, D., and Kerbel, R. S. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug resistant human breast cancer xenograft. Clin. Cancer Res., 8: 221-232, 2002.
8. Colleoni, M., Rocca, A., Sandri, M. T., Zorzino, L., Masci, G., Nole, F., Peruzzotti, G., Robertson, C., Orlando, L., Cinieri, S., De Braud, F., Viale, G., and Goldhirsch, A. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol., 13: 73-80, 2002.
9. Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., and Taraboletti, G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res., 2: 1843-1849, 1996.
10. Clements, M. K., Jones, C. B., Cumming, M., and Daoud, S. S. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother. Pharmacol. 44: 411-416, 1999.
11. Vacca, A., Iurlaro, M., Ribatti, D., Minischetti, M., Nico, B., Ria, R., Pellegrino, A., and Dammacco, F. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood, 94: 4143-4155, 1999.
12. Man, S., Bocci, G., Francia, G., Green, S., Jothy, S., Bergers, G., Hanahan, D., Bohlen, P., Hicklin, D. J., and Kerbel, R. S. Anti-tumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res., 62: 2731-2735, 2002.
13. Rose, W. C., Long, B. H., Fairchild, C. R., Lee, F. Y., and Kadow, J. F. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin. Cancer Res., 7: 2016-2021, 2001.
14. Nicolaou, K. C., Winssinger, N., Pastor, J., Ninkovic, S., Sarabia, F., He, Y., Vourloumis, D., Yang, Z., Li, T., Giannakakou, P., and Hamel, E. Synthesis of epothilones A and B in solid and solution phase. Nature (Lond.), 387: 268-272, 1997.
15. Nicolaou, K. C., Fylaktakidou, K. C., Mitchell, H. J., van Delft, F. L., Rodriguez, R. M., Conley, S. R., and Jin, Z. Total synthesis of everninomicin 13, 384-1-Part 4: Explorations of methodology; stereocontrolled synthesis of 1,1′-disaccharides. I. 2-Seleno migrations in carbohydrates, and solution- and solid-phase synthesis of 2-deoxy glycosides and orthoesters. Chemistry, 6: 3166-3185, 2000.
16. Nicolaou, K. C., Hepworth, D., King, N. P., Finlay, M. R., Scarpelli, R., Pereira, M. M., Bollbuck, B., Bigot, A., Werschkun, B., and Winssinger, N. Total synthesis of 16-desmethylepothilone B, epothilone B10, epothilone F, and related side chain modified epothilone B analogues. Chemistry. 6: 2783-2800, 2000.
17. Flowers, J. L., Ludeman, S. M., Gamcsik, M. P., Colvin, O. M., Shao, K. L., Boal, J. H., Springer, J. B., and Adams, D. J. Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide. Cancer Chemother. Pharmacol., 45: 335-344, 2000.
18. Tran. J., Master, Z., Yu, J., Rak, J., Dumont, D. J., and Kerbel, R. S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. USA, 99: 4349-4354, 2002.
19. Weitman, S. D., Glatstein, E., and Kamen, B. A. Back to the basics: The importance of concentration x time in oncology. J. Clin. Oncol., 11: 820-821, 1993.
20. Kamen, B. A., Rubin, E., Aisner, J., and Glatstein, E. High-time chemotherapy or high time for low dose. J. Clin. Oncol., 18: 2935-2937, 2000.
21. Giannakakou, P., Gussio, R., Nogales, E., Downing, K. H., Zaharevitz, D., Bollbuck, B., Poy, G., Sackett, D., Nicolaou, K. C., and Fojo, T. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. USA, 97: 2904-2909, 2000.
22. Bello, L., Carrabba, G., Giussani, C., Lucini, V., Cerutti, F., Scaglione, F., Landre, J., Pluderi, M., Tomei, G., Villani, R., Carroll, R. S., Black, P. M., L. B. P.P. M. and Bikfalvi, A. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res., 61: 7501-7506, 2001.
23. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays, 13: 31-36. 1991.
24. Gesi, M., Pellegrini, A., Soldani, P., Lenzi, P., Paparelli, A., Danesi, R., Nardini, D., and Macchia, M. Ultrastructural and biochemical evidence of apoptosis induced by a novel inhibitor of protein geranylgeranylation in human MIA PaCa-2 pancreatic cancer cells. Ultrastruct. Pathol., 22: 253-261, 1998.
25. Gu, W. Z., Tahir, S. K., Wang, Y. C., Zhang, H. C., Cherian, S. P., O'Connor, S., Leal, J. A., Rosenberg, S. H., and Ng, S. C. Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. Eur. J. Cancer, 35: 1394-1401, 1999.
26. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Sasazuki, T., and Kerbel, R. S. Mutant ras oncogenes up-regulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res., 55: 4575-4580, 1995.
27. Takahashi, N., Haba, A., Matsuno, F., and Seon, B. K. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between antiendoglin antibody and cyclophosphamide. Cancer Res., 61: 7846-7854, 2001.
28. Zhang, L., Yu, D., Hicklin, D. J., Hannay, J. A., Ellis, L. M., and Pollock, R. E. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res., 62: 2034-2042. 2002.
29. Soffer, S. Z., Moore, J. T., Kim, E., Huang, J., Yokoi, A., Manley, C., O'Toole, K., Stolar, C., Middlesworth, W., Yamashiro, D. J., and Kandel, J. J. Combination antiangiogenic therapy: Increased efficacy in a murine model of Wilms' tumor. J. Pediatr. Surg., 36: 1177-1181, 2001.
30. Alon, T., Hemo, I., Itin, A., Pe'er, J., Stone, J., and Keshet, E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med., 1: 1024-1028, 1995.
31. Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., and Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest., 103: 159-165, 1999.
32. Sweeney, C. J., Miller, K. D., Sissons, S. E., Nozaki, S., Heilman, D. K., Shen, J., and Sledge, G. W. J. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res., 61: 3369-3372, 2001.
33. Tran, J., Rak, J., Sheehan, C., Saibil, S. D., LaCasse, E., Korneluk, R. G., and Kerbel, R. S. Marked induction of the IAP family anti-apoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem. Biophys. Res. Commun., 264: 781-788, 1999.
34. Ezekowitz, R. A., Mulliken, J. B., and Folkman, J. Interferon α-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med., 326: 1456-1463, 1992.
35. Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P., and Fidler, I. J. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res., 5: 2726-2734, 1999.
36. Kisker, O., Becker, C. M., Prox, D., Fannon, M., D'Amato, R., Flynn, E., Fogler, W. E., Sim, B. K., Allred, E. N., Pirie-Shepherd, S. R., and Folkman. J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res., 61: 7669-7674, 2001.